Fig. 6.

ctDNA level in plasma correlated with patient prognosis. (a) Relative and absolute levels of ctDNA bearing a KRAS mutation in each individual. (b) Quantitative correlation between the relative and absolute levels of KRAS mutations (the size of the blue dots represents the total cfDNA concentration in each case). The (c) relative and (d) absolute levels of KRAS mutation in plasma strongly correlated with the overall survival of the patients. (e–f) The absolute level of KRAS mutation in plasma was superior to the relative fraction for prognostic prediction together with AJCC tumour staging (edition 7). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)